Aclarion CEO Brent Ness to Attend LSI USA 2026
Rhea-AI Summary
Aclarion (Nasdaq: ACON) announced that CEO Brent Ness will attend LSI USA 2026 in Dana Point, CA, March 16-20, 2026, to meet investors and potential partners.
Mr. Ness will discuss progress advancing NOCISCAN, Aclarion’s MR spectroscopy platform using biomarkers and AI to help identify painful vs non-painful spinal discs. Investors may request 1-on-1 meetings via the provided contact emails.
Positive
- None.
Negative
- None.
News Market Reaction – ACONW
In the Mar 12 session, ACONW gained 8.13%, reflecting a notable positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 05 | Shareholder letter | Positive | +3.1% | 2026 shareholder letter outlining clinical, financial, and operational priorities and timelines. |
| Feb 03 | Commercial expansion | Positive | -2.2% | Added Source Healthcare to support Nociscan growth and real-world evidence generation. |
| Jan 13 | Equity financing | Positive | -6.2% | Closed $10.4M common-stock financing, boosting cash to $21.6M and extending runway to 2028. |
| Jan 08 | Corporate outlook | Positive | +40.3% | Provided 2026 outlook with strong Nociscan volume growth and extended cash runway into H1 2027. |
| Jan 06 | Clinical trial update | Positive | -12.1% | Reported new CLARITY trial site enrollments and guidance on interim data timing. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent Aclarion news has been mostly positive, but price reactions are mixed, with 3 divergences and 2 alignments between news tone and next-day performance.
Over the past few months, Aclarion has focused on strengthening its balance sheet and advancing Nociscan and the CLARITY trial. A $10.4 million financing left the company debt-free with $21.6 million in cash and projected runway into 2028. Operational updates highlighted strong scan volume growth, new imaging centers and physician users, and progress toward enrolling up to 300 CLARITY patients. The current conference-attendance news fits into an ongoing push for investor awareness and commercial exposure around Nociscan.
Key Terms
biomarkers medical
augmented intelligence (AI) technical
mr spectroscopy medical
medtech technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
BROOMFIELD, Colo., March 12, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today that Brent Ness, Chief Executive Officer, will be attending LSI USA 2026, one of the leading conferences of global MedTech innovators, investors, and industry leaders.
During the event, Mr. Ness will meet with investors and potential industry partners to discuss Aclarion’s continued progress advancing NOCISCAN, the company’s proprietary MR spectroscopy platform that leverages AI and biomarkers to help physicians distinguish between painful and non-painful discs in patients suffering from chronic low back pain.
To schedule a 1-on-1 meeting with Mr. Ness, please email: ksmith@pcgadvisory.com.
LSI USA 2026
Dates: March 16-20, 2026
Location: Dana Point, CA
Format: In-person 1x1 Meetings
LSI USA ’26 is a premier event focused on accelerating MedTech and HealthTech innovation, bringing together investors, startups, and industry leaders.
For more News from Aclarion, please visit: Latest News
To find a Nociscan center, view our site map here.
For more information on Nociscan, please email: info@aclarion.com
About Aclarion, Inc.
Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (“MRS”), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan, the first, evidence-supported, SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. Biomarker data is entered into proprietary algorithms to indicate if a disc may be a source of pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain, giving physicians clarity to optimize treatment strategies. For more information, please visit www.aclarion.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 about the Company’s current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as “anticipates,” “believes” and “expects” or similar expressions, are forward-looking statements. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the Company’s current plans and expectations, as well as future results of operations and financial condition. Forward-looking statements in this release include, among others, statements regarding the enrollment of patients in our ongoing clinical trial, the potential benefits of our Nociscan technology, and the Company’s plans for future regulatory and commercialization activities. These and other risks and uncertainties are discussed more fully in our filings with the Securities and Exchange Commission. Readers are encouraged to review the section titled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, as well as other disclosures contained in the Prospectus and subsequent filings made with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Contacts:
Kirin M. Smith
PCG Advisory, Inc.
ksmith@pcgadvisory.com
Media Contacts:
Jennie Kim
SPRIG Consulting
jennie@sprigconsulting.com
